| Biomarker ID | 1156 |
| PMID | 23826311 |
| Year | 2013 |
| Biomarker | Peptide ID: 3495; 3506; 3621; 3992; 4437; 4679; 4697; 5180; 6832; 7661; 8698; 9483; 9645; 10502; 11899; 12083; 13995; 14592; 15331; 18990; 19773] |
| Biomarker Basis | Concentration Based |
| Biomolecule | Protein |
| Source | Plasma |
| Subjects | Humans |
| Regulation | Upregulated in PCa [mean(case)/mean(control)]: Downregulated in PCa [mean(control)/mean (case)]: [] |
| Odds Ratio/Hazard Ratio/Relative Risk | NA |
| Effect on Pathways | NA |
| Experiment | Prostate Cancer and Benign Prostatic Hyperplasia Vs inflammatory and healthy prostate |
| Type of Biomarker | Diagnostic |
| Cohort | 125 samples were divided into a discovery set with 22 PCa, 14 Chronic Prostatis; 9 BPH and 5 Healthy Control samples and the remaining 48 PCa, 12 BPH, 11 CP, and 4HC samples into an independent test set |
| Senstivity | NA |
| Specificity | NA |
| AUC | Training: 1.00 (95% CI .93–1.00) |
| Accuracy | NA |
| Level Of Significance | p< 0.0137 |
| Method Used | capillary electrophoresis mass spectrometry |
| Clinical | No |
| Remarks | NA |
| Clinical Trial Number | NA |
| Degree Of Validity | Validated on independent patient dataset |
| Technical Name | NA |